Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Transition Therapeutics Inc. Appoints New Chief Financial Officer
Transition Therapeutics Inc. announced the appointment of Ms. Nicole Rusaw-George, C.A., as Chief Financial Officer of Transition. Ms. George has been with the Company since 2005 and has served as Vice-President, Finance since 2008. While at Transition, Ms. George has been responsible for a broad range of activities with a focus on financial reporting and regulatory compliance as well as involvement in various equity financings and strategic acquisitions.
Latest Developments for Transition Therapeutics Inc
- Transition Therapeutics Inc Announces Results Of Clinical Study Of Type 2 Diabetes Drug Candidate TT-401
- Transition Therapeutics Inc. Announces Results Of Phase I Clinical Study Of TT-401
- Transition Therapeutics Inc. Announces Departure Of President And Chief Financial Officer
- Transition Therapeutics Inc. Completes USD5 Million Private Placement
Latest Key Developments in Pharmaceuticals
- AmerisourceBergen Corp Reaffirms FY 2013 EPS Gudiance-Conference Call
- Immunotec Inc Announces New CEO
- Novo Nordisk A/S Reports Positive Results from First Phase 3 Trial with Long-Acting Factor IX for Treatment of Haemophilia B
- Sanofi SA Announces Positive Results on Pivotal Study of Inhibitor in Myelofibrosis-DJ
- Share this
- Link this
- Digg this
Follow Reuters